Long-term advanced cholangiocarcinoma survivor with single-agent capecitabine

被引：0

作者：

Petekkaya, I. ^{[1
]}

Gezgen, G. ^{[1
]}

Roach, E. C. ^{[1
]}

Solak, M. ^{[1
]}

Altundag, K. ^{[1
]}

Gullu, I. ^{[1
]}

机构：

[1] Hacettepe Univ, Inst Canc, Dept Med Oncol, Ankara, Turkey

来源：

JOURNAL OF BUON | 2012年 / 17卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：796 / 796

页数：1

共 4 条

[1]

Parkin DM, 1992, CANC INCIDENCE 5 CON, V23

[2] Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma [J].

Patt, YZ ;

Hassan, MM ;

Aguayo, A ;

Nooka, AK ;

Lozano, RD ;

Curley, SA ;

Vauthey, JN ;

Ellis, LM ;

Schnirer, II ;

Wolff, RA ;

Charnsangavej, C ;

Brown, TD .

CANCER, 2004, 101 (03) :578-586

[3] Cholangiocarcinoma: A compact review of the literature [J].

Ustundag, Yucel ;

Bayraktar, Yusuf .

WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (42) :6458-6466

[4] Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. [J].

Valle, Juan ;

Wasan, Harpreet ;

Palmer, Daniel H. ;

Cunningham, David ;

Anthoney, Alan ;

Maraveyas, Anthony ;

Madhusudan, Srinivasan ;

Iveson, Tim ;

Hughes, Sharon ;

Pereira, Stephen P. ;

Roughton, Michael ;

Bridgewater, John .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (14) :1273-1281

← 1 →